EA200500122A1 - Новые соединения, фармацевтические композиции, содержащие их, и способы их использования - Google Patents

Новые соединения, фармацевтические композиции, содержащие их, и способы их использования

Info

Publication number
EA200500122A1
EA200500122A1 EA200500122A EA200500122A EA200500122A1 EA 200500122 A1 EA200500122 A1 EA 200500122A1 EA 200500122 A EA200500122 A EA 200500122A EA 200500122 A EA200500122 A EA 200500122A EA 200500122 A1 EA200500122 A1 EA 200500122A1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
cycloalkyl
alkenyl
alkyl
alkylaryl
Prior art date
Application number
EA200500122A
Other languages
English (en)
Other versions
EA010484B1 (ru
Inventor
Фрэнсис П. Кухаджа
Сьюзен М. Медгалчи
Джаган Н. Тхупари
Крэйг А. Таунсенд
Джилл М. Макфэдден
Original Assignee
Фасджен, Ллс.
Дзе Джонс Хопкинс Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фасджен, Ллс., Дзе Джонс Хопкинс Юниверсити filed Critical Фасджен, Ллс.
Publication of EA200500122A1 publication Critical patent/EA200500122A1/ru
Publication of EA010484B1 publication Critical patent/EA010484B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Abstract

Описывается фармацевтическая композиция, включающая фармацевтический разбавитель и соединение формулы IX R=H или C-C-алкил, циклоалкил, алкенил, арил, арилалкил или алкиларил, =CHR, -C(O)OR, -C(O)R, -CHC(O)OR, -CHC(O)NHR, где Rпредставляет H или C-C-алкил, циклоалкил или алкенил; R=C-C-алкил, циклоалкил, алкенил, арил, арилалкил или алкиларил; X=-ORили NHR, где Rпредставляет H, C-C-алкил, циклоалкил, алкенил, арил, арилалкил или алкиларил, причем, Rгруппа дополнительно содержит карбонильную группу, карбоксильную группу, карбоксамидную группу, спиртовую группу или простую эфирную группу, далее Rгруппа дополнительно содержит один или более атомов галогена; при условии, что когда Rпредставляет =CH, тогда Xне является группой -OH. Описываются также соединения, охватываемые объемом формулы IX, а также различные использования фармацевтических композиций для потери веса, противомикробного и противоопухолевого применения, ингибирования синтазы жирных кислот и нейропептида-Y и стимуляции активности карнитин-пальмитоил-трансферазы-1.Отчет о международном поиске был опубликован 2004.07.22.
EA200500122A 2002-07-01 2003-07-01 Новые соединения, фармацевтические композиции, содержащие их, и способы их использования EA010484B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39280902P 2002-07-01 2002-07-01
PCT/US2003/020960 WO2004006835A2 (en) 2002-07-01 2003-07-01 Novel compounds, pharmaceutical compositions containing same, and methods of use for same

Publications (2)

Publication Number Publication Date
EA200500122A1 true EA200500122A1 (ru) 2005-12-29
EA010484B1 EA010484B1 (ru) 2008-10-30

Family

ID=30115535

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500122A EA010484B1 (ru) 2002-07-01 2003-07-01 Новые соединения, фармацевтические композиции, содержащие их, и способы их использования

Country Status (15)

Country Link
US (1) US20060241177A1 (ru)
EP (1) EP1534263A4 (ru)
JP (1) JP2005533107A (ru)
KR (1) KR20050072670A (ru)
CN (2) CN101633650A (ru)
AU (1) AU2003248810B2 (ru)
BR (1) BRPI0312413A2 (ru)
CA (1) CA2491183A1 (ru)
EA (1) EA010484B1 (ru)
HK (1) HK1086485A1 (ru)
IL (1) IL166054A0 (ru)
MX (1) MXPA05000152A (ru)
SG (1) SG170620A1 (ru)
WO (1) WO2004006835A2 (ru)
ZA (1) ZA200500203B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9018737D0 (en) * 1990-08-28 1990-10-10 Goodfellow John W Phosphetic patellar components
KR20040082417A (ko) 2002-02-08 2004-09-24 존스 홉킨스 유니버시티 스쿨 오브 메디슨 체중 감량을 위한 수단으로서의 ｃｐｔ-1의 자극
CN101721412A (zh) * 2002-07-09 2010-06-09 法斯根有限责任公司 治疗人和动物中微生物感染的方法
CN101007796A (zh) * 2006-01-27 2007-08-01 北京摩力克科技有限公司 新型五元杂环化合物及其制备方法和医疗用途
CN101190904A (zh) * 2006-11-23 2008-06-04 中国人民解放军军事医学科学院毒物药物研究所 脂肪酸合成酶抑制剂及其制药用途
EP2581081A3 (en) 2007-06-01 2013-07-31 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
WO2010118324A2 (en) 2009-04-09 2010-10-14 Nuclea Biotechnologies, LLC Antibodies against fatty acid synthase
FR2957078B1 (fr) 2010-03-05 2012-05-04 Centre Nat Rech Scient Acides paraconiques comme activateurs de pigmentation
EP2566853B1 (en) 2010-05-05 2017-01-25 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
US20150099730A1 (en) * 2012-09-07 2015-04-09 Janssen Pharmaceutica, Nv Imidazolin-5-one derivative useful as fasn inhibitors for the treatment of cancer
CN103145662B (zh) * 2013-02-18 2014-07-16 深圳万和制药有限公司 N-取代的氨基丁内酯衍生物及其用途
CN103880789B (zh) * 2014-02-19 2016-02-03 成都中医药大学 呋喃内酯环类衍生物及其用途
CN104530018B (zh) * 2014-12-12 2017-04-12 郑州大学 含α‑亚甲基‑γ‑丁内酯结构的吲哚类化合物、制备方法及其应用
EP3253742B1 (en) * 2015-02-05 2020-04-08 Dermira Inc. Synthetic process for preparing 2-((2-ethoxy-2-oxoethyl)(methyl)amino)-2-oxoethyl 5-tetradecyloxy)furan-2-carboxylate
KR102038971B1 (ko) * 2018-03-12 2019-11-26 주식회사 엔지켐생명과학 디아실글리세롤락톤 화합물, 그 제조방법 및 이를 유효성분으로 함유하는 면역증진제
KR20220159831A (ko) 2021-05-26 2022-12-05 울산과학기술원 미토콘드리아 표적화 뉴클레오펩티드 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496187A (en) * 1967-03-20 1970-02-17 American Home Prod N-(heterocyclyl)aconamides
US3472878A (en) * 1969-01-27 1969-10-14 American Home Prod N-(hydroxyaryl)aconamides
US4753871A (en) * 1986-12-12 1988-06-28 Eastman Kodak Company Cyan dye-forming couplers and photographic materials containing same
JPS63169848A (ja) * 1987-01-07 1988-07-13 Nec Corp デジタルデ−タ通信におけるデ−タ端末収容方式
JP2524760B2 (ja) * 1987-07-10 1996-08-14 テイカ株式会社 新規抗生物質
JPH04199148A (ja) * 1990-11-29 1992-07-20 Konica Corp ハロゲン化銀写真感光材料
JPH05246822A (ja) * 1992-03-07 1993-09-24 Nippon Paint Co Ltd 抗菌剤
JPH07112931A (ja) * 1993-08-27 1995-05-02 Nippon Paint Co Ltd エプスタイン−バーウイルス活性化抑制剤
ATE303144T1 (de) * 1995-11-17 2005-09-15 Univ Johns Hopkins Hemmung der fettsäuresynthase als mittel zur verminderung der adipozytenmenge
CA2391277A1 (en) * 1999-11-12 2001-05-17 The Johns Hopkins University School Of Medicine Treating cancer by increasing intracellular malonyl coa levels
JP2003528051A (ja) * 2000-02-16 2003-09-24 ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン ニューロペプチドｙレベルの減少によって誘導される体重減少

Also Published As

Publication number Publication date
EP1534263A2 (en) 2005-06-01
BRPI0312413A2 (pt) 2016-08-02
ZA200500203B (en) 2009-09-30
MXPA05000152A (es) 2005-10-24
CN100482219C (zh) 2009-04-29
SG170620A1 (en) 2011-05-30
KR20050072670A (ko) 2005-07-12
EA010484B1 (ru) 2008-10-30
WO2004006835A3 (en) 2004-07-22
JP2005533107A (ja) 2005-11-04
CN101633650A (zh) 2010-01-27
IL166054A0 (en) 2006-01-15
HK1086485A1 (en) 2006-09-22
CA2491183A1 (en) 2004-01-22
US20060241177A1 (en) 2006-10-26
AU2003248810B2 (en) 2009-08-20
EP1534263A4 (en) 2006-10-11
WO2004006835A2 (en) 2004-01-22
CN1705478A (zh) 2005-12-07
AU2003248810A1 (en) 2004-02-02

Similar Documents

Publication Publication Date Title
EA200500122A1 (ru) Новые соединения, фармацевтические композиции, содержащие их, и способы их использования
EA200000334A1 (ru) Производные карбоксамидотиазолов, их получение, содержащие их фармацевтические композиции
ES2044836T3 (es) Derivado de la piperidina, su utilizacion y compuesto farmaceutico que lo contiene.
DE69512797T2 (de) Prostaglandin-synthase hemmer
FR2391999A1 (fr) Derives de cyclohexane a utiliser comme herbicides selectifs
EA200500178A1 (ru) Новые соединения, содержащие их фармацевтические композиции и способы их применеия
FR2446820A1 (fr) 6-oxo-7-(dimithylaminomethylene) decahydroquinoleines utiles comme intermediaires de synthese
KR850007975A (ko) 6-클로로벤즈아졸릴옥시아세트아미드의 제조방법
DE60332350D1 (de) Disazofarbstoffe und sie enthaltende tintenstrahldrucktinten
CA2011087A1 (en) Use of trifluoromethylphenylazolylmethyloxiranes as crop protection agents
SE8002345L (sv) Terapeutiska medel
FR2372817A1 (fr) Derives d'acides thiazolidinecarboxyliques et d'acides apparentes, utiles comme agents anti-hypertension
SE7601143L (sv) Nytt oxadiazolinonderivat
EP1465488A4 (en) ARYLAMINES AS INHIBITORS OF THE BINDING OF CHEMOKINE A US28
YU47219B (sh) Antivirusna tetrahidroimidazo (1,4) benzodiazepin-2-tiona jedinjenja i postupak za njihovo dobijanje
RU95116352A (ru) Производные 4-бензоилизоксазолов и их использование в качестве гербицидов
EA200601092A1 (ru) Фунгицидные смеси на основе производных карбаматов и инсектицидов
EA200200939A1 (ru) Способ получения циталопрама
ATE428693T1 (de) Prostaglandinsynthese
EA200400806A1 (ru) Способ получения эхинокандиновых соединений
TR22774A (tr) Fungisid maddeler olarak subsitituee edilmis hidroksialkilazoller,bunlarin hazirlanmasina ve kullanimi
EA200100059A3 (ru) Новые бензолсульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
EA200200523A1 (ru) Новые разветвленные замещенные аминопроизводные 3-амино-1-фенил-1h[1,2,4]триазола, способы их получения и содержащие их фармацевтические композиции
SE7903687L (sv) Cyklohexylkarboxylsyraderivat och sett att framstella desamma
FI963168A0 (fi) Enkefalinaasin inhibiittoreina käyttökelpoisia uusia indaani-2-merkaptoasetyyliamiddisulfidijohdannaisia

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU